Ocular Involvement of Behcet's Syndrome: a Comprehensive Review

被引:44
作者
Ozyazgan, Yilmaz [1 ]
Ucar, Didar [1 ]
Hatemi, Gulen [2 ]
Yazici, Yusuf [3 ]
机构
[1] Istanbul Univ, Dept Ophthalmol, Cerrahpasa Med Sch, Istanbul, Turkey
[2] Istanbul Univ, Cerrahpasa Med Sch, Dept Internal Med, Div Rheumatol, Istanbul, Turkey
[3] NYU, Hosp Joint Dis, New York, NY 10016 USA
关键词
Behcet; Uveitis; Eye; Retinal vasculitis; Prognosis; Treatment; SIGHT THREATENING UVEITIS; INTERFERON-ALPHA; REFRACTORY UVEORETINITIS; CLINICAL-FEATURES; CYCLOSPORINE-A; MASKED TRIAL; DISEASE; INFLIXIMAB; EFFICACY; THERAPY;
D O I
10.1007/s12016-014-8425-z
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Behcet's syndrome (BS) is a vasculitis involving several organ systems including the eyes. Ocular involvement is one of the most disabling complications of BS, causing loss of vision that may progress to blindness if left untreated. The typical form of ocular involvement is a relapsing and remitting panuveitis and retinal vasculitis. Initial attacks may spontaneously improve and subsequently disappear in a few weeks but tend to recur if left untreated. Destructive and recurrent attacks, especially with posterior segment and retina involvement, may cause irreversible ocular structural changes and permanent damage in sensory retina, resulting in loss of vision. The risk of irreversible damage to ocular tissue which may result in loss of vision warrants early and intensive treatment especially in patients at high risk such as young men who tend to follow an aggressive disease course. The management strategy involves rapid suppression of inflammation during the attacks and prevention of recurrent attacks. Local and systemic measures including immunosuppressives, corticosteroids, and biologic agents are used for this purpose. Surgery may be required in selected cases. The prognosis of eye involvement has greatly improved over the last decades with the effective use of immunosuppressives.
引用
收藏
页码:298 / 306
页数:9
相关论文
共 43 条
[1]   Clinical Experience with Adalimumab in the Treatment of Ocular Behcet Disease [J].
Bawazeer, Ahmed ;
Raffa, Lina H. ;
Nizamuddin .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2010, 18 (03) :226-232
[2]  
BENEZRA D, 1988, TRANSPLANT P, V20, P136
[3]   Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors [J].
Bodaghi, B ;
Quoc, EB ;
Wechsler, B ;
Tran, THC ;
Cassoux, N ;
Huong, DLT ;
Chosidow, O ;
Herson, S ;
Piette, JC ;
LeHoang, P .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (06) :962-964
[4]   Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients [J].
Bodaghi, Bahram ;
Gendron, Gael ;
Wechsler, Bertrand ;
Terrada, Celine ;
Cassoux, Nathalie ;
Huong, Du Le Thi ;
Lemaitre, Claire ;
Fradeau, Christine ;
LeHoang, Phuc ;
Piette, Jean-Charles .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (03) :335-339
[5]   Comparison of Presenting Features and Three-year Disease Course in Turkish Patients with Behcet Uveitis Who Presented in the Early 1990s and the Early 2000s [J].
Cingu, Abdullah Kursat ;
Onal, Sumru ;
Urgancioglu, Meri ;
Tugal-Tutkun, Ilknur .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2012, 20 (06) :423-428
[6]   INTERFERON-ALPHA-2B FOR REFRACTORY OCULAR BEHCETS-DISEASE [J].
DURAND, JM ;
SOUBEYRAND, J .
LANCET, 1994, 344 (8918) :333-333
[7]  
Ehrlich G E, 1997, Int Rev Immunol, V14, P81, DOI 10.3109/08830189709116846
[8]  
Emmi G, 2013, CLIN EXP RHEUMATOL, V31, pS152
[9]   Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study [J].
Gul, Ahmet ;
Tugal-Tutkun, Ilknur ;
Dinarello, Charles A. ;
Reznikov, Leonid ;
Esen, Bahar Artim ;
Mirza, Amer ;
Scannon, Patrick ;
Solinger, Alan .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (04) :563-566
[10]   Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop [J].
Jabs, DA ;
Nussenblatt, RB ;
Rosenbaum, JT .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2005, 140 (03) :509-516